Manages cystic fibrosis (CF). Sold as Pulmozyme. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Dornase Alfa (sold as Pulmozyme), first approved Dec 30, 1993, with 3 new uses approved and 0 published complete response letters.
| Pulmozyme | Part B | $24.5M | +6% | 900 |
| Pulmozyme | Part D | $2.5M | +21% | 104 |
| Efficacy and Safety of Intrapleural Fibrinolytic Therapy in Tuberculous Pleural Effusion Versus Non-Tuberculous Pleural InfectionTuberculous Pleural Effusion · National University of Malaysia | — | Not yet recruiting | Sep 16, 2026 |
| Rethinking Early Airway Clearence TherapiesCystic Fibrosis (CF) · Nicole Hamblett | Not applicable | Not yet recruiting | Jul 10, 2026 |
| Flush, Lyse, OperateComplicated Parapneumonic Effusion, Empyema, Pleural · Dartmouth-Hitchcock Medical Center | Phase 4 | Not yet recruiting | May 18, 2026 |
| Intrapleural Alteplase-Tyloxapol vs Intrapleural Alteplase-DNase in Pleural InfectionPleural Infection · National University of Malaysia | — | Recruiting | Feb 25, 2026 |
| Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.Large B-Cell Lymphoma (LBCL) · Tel-Aviv Sourasky Medical Center | Phase 1 | Recruiting | Jan 22, 2026 |
| Dornase Alfa and Cisplatin in Refractory Germ Cell Cancer.Refractory Germ Cell Tumors, Dornase Alfa · National Cancer Institute, Slovakia | Phase 2 | Recruiting | Aug 13, 2025 |
| Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 MonthsRuptured Aneurysm of Intracranial Artery, SAH (Subarachnoid Hemorrhage) · Fondation Ophtalmologique Adolphe de Rothschild | Phase 2 | Recruiting | Dec 9, 2024 |
| Reduction of SystemiC Inflammation After Ischemic Stroke by Intravenous DNase Administration (ReSCInD)Ischemic Stroke, Inflammatory Response · Ludwig-Maximilians - University of Munich | Phase 2 | Recruiting | May 30, 2023 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
